Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research note

Time to resolution of respiratory and systemic coronavirus disease 2019 symptoms in community setting

Aurélien Dinh¹,²,*, Luc Jaulmes³, Agnès Dechartres⁴, Clara Duran¹, Hélène Mascitti¹, Xavier Lescure²,⁵, Youri Yordanov⁶, Patrick Jourdain²,⁷, on behalf of the AP-HP/Universities/INSERM COVID-19 research collaboration

¹) Infectious Disease Department, University Hospital Raymond-Poincaré, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Garches, France
²) Covidom regional telemedicine platform, Assistance Publique-Hôpitaux de Paris, Paris, France
³) Clinical Research and Epidemiology Department, University Hospital Pitie-Salpetrière, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
⁴) Sorbonne Université, INSEEM, Institut Pierre Louis d’Épidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Paris, France
⁵) Infectious Disease Department, University Hospital Bichat, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
⁶) Emergency Department, University Hospital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France
⁷) Cardiology Department, University Hospital of Bicêtre, Assistance Publique-Hôpitaux de Paris, Kremlin Bicêtre, France

Article info

Article history:
Received 29 June 2021
Received in revised form 17 August 2021
Accepted 21 August 2021
Available online 3 September 2021
Editor: L. Leibovici

Keywords:
Community setting
Coronavirus disease 2019
Dyspnoea
Sequelae
Symptom duration
Telemedicine

Abstract

Objectives: To assess the time to resolution of respiratory and systemic symptoms and their associated factors in outpatients during the coronavirus disease 2019 (COVID-19) pandemic.

Methods: Cohort study including adult outpatients, managed with Covidom, a telesurveillance solution, with RT-PCR-confirmed diagnosis, from 9 March 2020 until 23 February 2021. Follow up was 30 days after symptom onset.

Results: Among the 9667 patients included, mean age was 43.2 ± 14.0 years, and 67.5% were female (n = 6522). Median body mass index (BMI) was 25.0 kg/m² (interquartile range 22.1–28.8 kg/m²). Main co-morbidities were: hypertension (12.9%; n = 1247), asthma (11.0%; n = 1063) and diabetes mellitus (5.5%; n = 527). The most frequent symptom during follow up was dyspnoea (65.1%; n = 6296), followed by tachypnoea (49.9%; n = 4821), shivers (45.6%; n = 4410) and fever (36.7%; n = 3550). Median times to resolution of systemic and respiratory symptoms were 3 days (95% CI 2–4 days) and 7 days (95% CI 6–8 days), respectively. Ultimately, 17.2% (95% CI 15.7%–18.8%) still presented respiratory symptoms at day 30. Longer time to respiratory symptom resolution was associated with older age, increased BMI, chronic obstructive pulmonary disease, coronary artery disease, asthma and heart failure. Regarding systemic symptoms, coronary artery disease, asthma, age above 40 years and elevated BMI were associated with longer time to resolution.

Conclusions: Time to symptom resolution among outpatients with COVID-19 seemed shorter for systemic than respiratory symptoms. Prolonged respiratory symptoms were common at day 30. Risk factors associated with later resolution included age, and cardiovascular and pulmonary diseases.

Aurélien Dinh, Clin Microbiol Infect 2021;27:1862.e1 – 1862.e4

© 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
The clinical manifestations in individuals with coronavirus disease 2019 (COVID-19) range from asymptomatic to severe forms requiring critical care, and the duration of symptoms can vary widely [1,2]. Most studies described the clinical course of hospitalized severe cases [3–5]. However, most patients present with milder forms of COVID-19 [6], and are therefore managed as outpatients. Data on this population are scarce, but describing the symptom course of outpatients with COVID-19 and factors associated with symptom duration may help provide adequate follow up [2,7–9].

Our study aimed to evaluate the time to resolution of COVID-19 respiratory and systemic symptoms, and factors associated with a longer duration in a large cohort of outpatients.

Materials and methods
This study included adults (≥18 years), initially managed as outpatients, from 9 March 2020 to 23 February 2021 by Covidom, a telesurveillance solution for home monitoring of patients with COVID-19 in the greater Paris area [10]. Covidom outpatients were registered by a physician after consulting for COVID-related symptoms and agreeing to the monitoring. We included patients with an RT-PCR-confirmed diagnosis, having answered at least one monitoring questionnaire, and who provided medical background at inclusion. Available data for each patient included age, gender, date of first symptoms, weight, height and co-morbidities.

When included in Covidom, the patients completed, on a daily basis, one or two self-administered questionnaires on symptoms until 30 days after symptom onset. Self-reported data were: respiratory rate (tachypnoea defined as >20 breaths per minute), heart rate (tachycardia defined as >100 beats per minute), temperature (fever and hypothermia defined as temperatures >38.5°C and <35.5°C, respectively), dyspnoea (on a 1-to-5 modified Borg scale [11], slight dyspnoea defined as a rating >2, and moderate dyspnoea by ≥3), oxygen saturation (desaturation defined as <95%), dizziness and shivers.

Two main groups of symptoms were defined:

- Systemic symptoms: fever or hypothermia, dizziness, tachycardia, shivers.
- Respiratory symptoms: dyspnoea, tachypnoea, low oxygen saturation.

Kaplan–Meier estimators were used to evaluate time to resolution of symptoms. Patients were considered at risk from the date of first symptom onset (declared at inclusion) until the last occurrence of each symptom in daily questionnaires. Regarding symptom groups, patients were considered at risk until the last day of any symptom occurrence of the group. Patients were censored at the end of their follow up (30 days or earlier in case of premature ending). Factors independently associated with longer time to resolution of systemic and respiratory symptoms were evaluated separately on complete cases using multivariate Cox models and inverse hazard ratios as the event of interest was initially resolution of symptoms. α risk was set at 5%.

Patients provided electronic consent for the Covidom telesurveillance program and were informed of the use of their anonymized data for research. This study was approved by the scientific and ethical committee of the Assistance Publique-Hôpitaux de Paris (IRB00011591).

Results
Among the 62 993 patients included in the Covidom cohort as outpatients, 15 086 (23.9%) had a COVID-19 RT-PCR-confirmed diagnosis, 14 965 (23.8%) were adults, 11 984 (19.0%) answered at least one monitoring questionnaire and 9667 (15.3%) provided medical background at inclusion and so were included in this study (patients characteristics are presented in Table S1 in the Supplementary material).

Mean age was 43.2 years old (SD 14.0) and 67.5% were female (n = 6522). Median body mass index (BMI) was 25.0 kg/m² (interquartile range (IQR) 22.1–28.8 kg/m²). Main co-morbidities were hypertension (12.9%; n = 1247), asthma (11.0%; n = 1063) and diabetes mellitus (5.5%; n = 527). Other co-morbidities were reported by less than 1.5% of patients. Data on weight (and BMI) was missing for 121 patients, and on gender for 18 patients.

The last answer to a daily questionnaire occurred at a median of 28 days after symptom onset (IQR 17–30 days), with a median Covidom monitoring duration of 19 days (IQR 11–24 days). There were 65.1% of patients (n = 7805) who were missing at least one daily monitoring questionnaire, and the median number of skipped questionnaires per patient was 2 (IQR 0–5).

The most common symptom was dyspnoea in 65.1% of patients (n = 6296), with 2802 patients (29.0%) rating their dyspnoea as moderate or higher. Tachypnoea, shivers and fever were reported by 49.9% (n = 4821), 45.6% (n = 4410) and 36.7% (n = 3550) of patients, respectively. A total of 2590 (26.8%) patients reported tachycardia, 1197 (12.4%) reported dizziness and 582 (25.1%) of 2319 patients with an oximeter reported desaturation at last once.

Considering time to symptom resolution (Fig. 1), the longest symptoms were desaturation with a median (95% CI) of 10 days (8–12 days), and slight dyspnoea with a median of 9 days (7–10 days). Median time to resolution of moderate dyspnoea was 4 days (2–5 days). Symptoms with shorter time to resolution included shivers, tachypnoea and tachycardia, with median durations (95% CI) respectively of 1 day (1–2 days), 2 days (1–2 days) and 2 days (1–2 days). The probability of slight dyspnoea lasting until 30 days after onset of first symptoms was 18.3% (95% CI 16.6%–20.0%), whereas the systemic symptom with highest probability at day 30 was dizziness with 11.1% (0.5%–2.2%).

Age above 30 years (hazard ratio (HR) 1.27; 95% CI 1.16–1.38), 40 years (HR 1.50; 95% CI 1.37–1.65), 50 years (HR 1.68; 95% CI 1.53–1.85) and 60 years (HR 1.64; 95% CI 1.45–1.84), as well as increased BMI (both obesity and overweight, HR 1.13; 95% CI 1.15–1.21 and HR 1.18; 95% CI 1.09–1.28, respectively), chronic obstructive pulmonary disease (HR 2.00; 95% CI 1.41–2.83), coronary artery disease (HR 1.55; 95% CI 1.14–2.11), asthma (HR 1.43; 95% CI 1.30–1.58), heart failure (HR 1.42; 95% CI 1.08–1.86) and hypertension (HR 1.12; 95% CI 1.01–1.23) were associated with longer time to resolution of respiratory symptoms (Fig. 2). No variable appeared to be associated with a shorter time to resolution.

For systemic symptoms, coronary artery disease (HR 1.53; 95% CI 1.18–1.98), as well as age above 40 years (HR 1.12; 95% CI 1.02–1.22, HR 1.16; 95% CI 1.06–1.26 and HR 1.20; 95% CI 1.08–1.34, respectively for ages >40, >50 and > 60 years) and increased BMI (HR 1.09; 95% CI 1.03–1.16 for BMI >25 kg/m², HR 1.10; 95% CI 1.03–1.18 for BMI >30 kg/m²) were associated with longer time to resolution (Fig. 2). Male sex was associated with shorter time to resolution (HR 0.92; 95% CI 0.87–0.97). Complete analysis results are presented in Table S2 in the Supplementary material.
Lastly, the number and proportion of patients per monitoring question, answer and day are described in Fig. S1 in the Supplementary material.

**Discussion**

Our study provides important inputs regarding time to resolution of respiratory and systemic symptoms over 1 month in ambulatory patients, which can help direct care [5,12-14]. Median time to resolution of symptoms was up to 10 days with wide variability, and 18.3% of slight dizziness symptoms still present at end of follow up. Systemic symptoms were slightly less frequent than respiratory symptoms, and had a shorter time to resolution. Factors associated with prolonged symptoms included age over 30 years, elevated BMI, and cardiovascular and pulmonary diseases. The strength of our study includes the size of the cohort and the standardized questionnaire during the entire 30-day follow up.
Several studies showed, among hospitalized patients, that fever, cough, dyspnoea and gastrointestinal symptoms were the main clinical manifestations of COVID-19 [15]. In our cohort that included only non-hospitalized patients, those symptoms had a lower prevalence.

Our results corroborate that COVID-19 may cause prolonged symptoms, even among outpatients with mild disease [2], or in patients with or without few co-morbidities.

**Limits**

Our study relies on patients’ self-reporting, resulting in possible recall bias. Furthermore, we focused on general and respiratory symptoms and did not evaluate the duration of other symptoms like smell and taste alteration. Second, non-respondents might have differed from respondents regarding their clinical course. Finally, our models do not take into account each symptom’s onset delay, only the date until which each symptom lasts, starting from the onset of the first symptom. This describes the course of symptoms relative to the illness globally, but different factors may affect symptom onset delay and symptom duration.

**Conclusion**

Time to symptom resolution in outpatients with COVID-19 varies widely with shorter systemic symptoms and longer respiratory symptoms. Prolonged respiratory symptoms, especially dyspnoea, were common at day 30. Factors associated with later resolution were age over 30 years, elevated BMI, and cardiovascular and pulmonary diseases.

**Transparency declaration**

The authors declare that they have no conflicts of interest. All authors have full control of all primary data and they agree to allow review of their data upon request.

**Fundings**

This study received a funding by the Programme Hospitalier de Recherche Clinique 2020 of the French Ministry of Health, by a research fund by APHP-Fondation de France. The Covidom platform received a funding from EIT Health specific COVID-19 fund.

**Authors’ contributions**

ADI, LJ, ADe, XL and YY conceptualized the study. ADi, LJ, ADe, CD, HM and YY collected, analysed and interpreted the data. LH conducted the statistical analysis. ADi, LJ, ADe, CD and YY wrote the first draft of the manuscript. All authors revised the manuscript and approved the final version. ADi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.08.021.

**References**

[1] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
[2] Tenforde MW, Kim SS, Londell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multisite health care systems network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep 2020;69:993–8.
[3] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;m1985.
[4] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[5] Mizrahi B, Shilo S, Rossman H, Kalkstein N, Marcus K, Barer Y, et al. Longitudinal symptom dynamics of COVID-19 infection. Nat Commun 2020;11:6208.
[6] Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus 2019 disease case surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65.
[7] Pullen MF, Skipper CP, Hullisiek RH, Bandiwala AS, Pastick KA, Okafor EC, et al. Symptoms of COVID-19 outpatients in the United States. Open Forum Infect Dis 2020;7.https://doi.org/10.1093/ofid/ofaa271.
[8] Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J, et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med 2020;15:813–7.
[9] Kim G-U, Kim M-J, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 2020;26:948. e1–948.e3.
[10] Yordanov Y, Dechartres A, Lescure X, Apca G, Ville P, Marchand-Arvier J, et al. Covidom, a telesurveillance solution for home monitoring patients with COVID-19. J Med Internet Res 2020;22.https://doi.org/10.2196/20748.
[11] Muza SK, Silverman MT, Gilmore GC, Hellerstein HK, Kelsen SG. Comparison of scales used to quantify the sense of effort to breathe in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990;141:909–13.
[12] The Lancet. Facing up to long COVID. Lancet 2020;396:1861.
[13] Davido B, Seang S, Tubiana R, de Truchis P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect 2020;26:1448–9.
[14] Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courtier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med 2021;174:723–5.
[15] Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35:1545–9.